Stock Events

Stock Events

ALK-Abello AS 

$33.33
59
-$2.77-7.69% Monday 20:00

Statistics

Day High
36.1
Day Low
36.1
52W High
36.14
52W Low
19.9
Volume
100
Avg. Volume
23
Mkt Cap
6.75B
P/E Ratio
47.14
Dividend Yield
0.75%
Dividend
0.25

Upcoming

18
MAR
Dividend Ex
Increased
 
19
MAR
Dividend Payment
Increased
 
18
MAR 27
Dividend Ex
Estimated
 
19
MAR 27
Dividend Payment
Estimated
 
20
MAR 28
Dividend Ex
Estimated
 

Dividends

0.75%Dividend Yield
Mar 26
$0.25
Mar 17
$0.05
Mar 16
$0.05
Mar 15
$0.05
Mar 14
$0.05
10Y Growth
17.65%
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

5MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
0.11
0.15
0.19
0.23
Expected EPS
N/A
Actual EPS
N/A

Financials

18.3%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.97BRevenue
359.84MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AKBLF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Merck & Co., through its subsidiary, produces allergy immunotherapy treatments similar to ALK-Abello, making them direct competitors in the allergy solutions market.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc offers a range of allergy-related pharmaceutical products, competing in the same space as ALK-Abello with their allergy and respiratory products.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a portfolio that includes treatments for respiratory conditions, including allergies, directly competing with ALK-Abello's allergy immunotherapy products.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, through its divisions, provides healthcare solutions that compete with ALK-Abello, including treatments for asthma and COPD, which are often related to allergies.
Sanofi
SNY
Mkt Cap124.45B
Sanofi offers a range of treatments for allergies and respiratory conditions, making it a competitor to ALK-Abello in the market for allergy treatments.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb has a diverse biopharmaceutical portfolio that includes treatments for a variety of conditions, including those that compete with ALK-Abello's allergy solutions.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio of medicines and vaccines, including products for allergies and respiratory conditions, competing with ALK-Abello.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries Limited manufactures generic drugs, including those for allergies and respiratory conditions, making it a competitor to ALK-Abello.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is known for its innovative treatments in areas including allergies, directly competing with ALK-Abello's allergy immunotherapy products.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment, offers products that compete in the allergy and respiratory market, making it a competitor to ALK-Abello.

About

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Show more...
CEO
Mr. Peter Halling
Employees
2736
Country
DK
ISIN
DK0061802139

Listings

CO
DK
ALK-B.CO
F
DE
4AJ0.F
OTC Link
US
AKBLF
LSE
GB
0OIR.LSE

0 Comments

Share your thoughts

FAQ

What is ALK-Abello AS stock price today?▼
The current price of AKBLF is $33.33 USD — it has decreased by -7.69% in the past 24 hours. Watch ALK-Abello AS stock price performance more closely on the chart.
What is ALK-Abello AS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ALK-Abello AS stocks are traded under the ticker AKBLF.
What is ALK-Abello AS market cap?▼
Today ALK-Abello AS has the market capitalization of 6.75B
When is the next ALK-Abello AS earnings date?▼
ALK-Abello AS is going to release the next earnings report on May 05, 2026.
What were ALK-Abello AS earnings last quarter?▼
AKBLF earnings for the last quarter are 0.19 USD per share, whereas the estimation was 0.2 USD resulting in a -7.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ALK-Abello AS revenue for the last year?▼
ALK-Abello AS revenue for the last year amounts to 1.97B USD.
What is ALK-Abello AS net income for the last year?▼
AKBLF net income for the last year is 359.84M USD.
Does ALK-Abello AS pay dividends?▼
Yes, AKBLF dividends are paid annual. The last dividend per share was 0.05 USD. As of today, Dividend Yield (FWD)% is 0.75%.
How many employees does ALK-Abello AS have?▼
As of March 12, 2026, the company has 2,736 employees.
In which sector is ALK-Abello AS located?▼
ALK-Abello AS operates in the Health Care sector.
When did ALK-Abello AS complete a stock split?▼
The last stock split for ALK-Abello AS was on March 29, 2022 with a ratio of 20:1.
Where is ALK-Abello AS headquartered?▼
ALK-Abello AS is headquartered in Horsholm, DK.